A recent study demonstrated the preliminary efficacy and safety of palbociclib in AM treatment, suggesting that MCM7 and the JAK-STAT pathway could serve as potential biomarkers for CDK4/6 inhibitors in AM. Here, CDK4 is linked to acute myeloblastic leukemia with maturation.